A Service For Professionals Friday, August 18, 2017
Contact (202) 540-8337

Company News Today

A Service For Professionals Friday, August 18, 2017 11424 Sources 398,867,854 Articles 3,328,029 Readers
Contact (202) 540-8337

Insmed to Present at the JMP Securities Life Sciences Conference

BRIDGEWATER, N.J., June 13, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, announced today that Will Lewis, president and chief executive officer of Insmed, will present at the JMP Securities Life Sciences Conference in New York, NY on Tuesday, June 20, 2017 at 3:30 p.m. ET.

/EIN News/ -- Mr. Lewis’ presentation will be webcast live and can be accessed by visiting the investor relations section of the company’s website at www.insmed.com. The webcast will be archived for a period of 90 days following the conclusion of the live event.

About Insmed

Insmed Incorporated is a global biopharmaceutical company focused on the unmet needs of patients with rare diseases. The company is advancing a global phase 3 clinical study of ARIKAYCE® (liposomal amikacin for inhalation) for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC), which is a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. There are currently no approved inhaled products specifically indicated for the treatment of refractory NTM lung disease caused by MAC in the United States or the European Union. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of DPP1 with therapeutic potential in non-cystic fibrosis bronchiectasis, and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. For more information, visit www.insmed.com.

"Insmed" and "ARIKAYCE" are the company's trademarks. All other trademarks, trade names or service marks appearing in this press release are the property of their respective owners.

Investor Contact:
                    
                    Laura Perry or Heather Savelle
                    Argot Partners
                    212-600-1902
                    laura@argotpartners.com
                    heather@argotpartners.com

Primary Logo

Powered by EIN News